David Bromet, MD
Interventional Cardiology · Crystal Lake, ILNPI 1841250958
Payments from drug & device makers
Across 258 payments — averaging $49.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Penumbra, Inc.$2K
- Edwards Lifesciences$1K
- Terumo Medical Corporation$1K
- Abbott$934
- E.r. Squibb & Sons, L.L.C.$589
- plus $3K from 32 others
What the payments were for
- Travel & lodging$6,93954%
- Food & beverage$5,84046%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 44 | $3,463 |
| Penumbra, Inc. | 5 | $2,392 |
| Edwards Lifesciences | 25 | $1,353 |
| Terumo Medical Corporation | 8 | $1,118 |
| Abbott | 12 | $934 |
| E.r. Squibb & Sons, L.L.C. | 53 | $589 |
| Abiomed | 7 | $437 |
| Boston Scientific | 8 | $251 |
| Heartflow, Inc. | 10 | $194 |
| Stryker | 9 | $180 |
| AstraZeneca | 7 | $169 |
| Esperion Therapeutics, Inc. | 3 | $164 |
| Cardiva Medical, Inc. | 8 | $163 |
| Boehringer Ingelheim | 9 | $158 |
| Merck | 7 | $155 |
| Cardiovascular Systems Inc. | 4 | $111 |
| GE HealthCare | 1 | $108 |
| Novartis | 5 | $107 |
| Bridgebio Pharma, Inc. | 2 | $95 |
| Kestra Medical Technology Services, Inc. | 2 | $87 |
| Bayer | 3 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $66 |
| Pfizer | 2 | $46 |
| Johnson & Johnson | 3 | $43 |
| Amgen | 2 | $42 |
| Intuitive Surgical | 1 | $37 |
| Recor Medical Inc | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Bard Peripheral Vascular, Inc. | 2 | $31 |
| Cvrx, Inc. | 1 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Cordis US CORP. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Surmodics, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$3,540
- VenaSeal$2,337
- Navicross$871
- Glidesheath$595
- GlideWire$595
- Edwards SAPIEN 3 Transcatheter Heart Valve$590
- DRAGONFLY OPSTAR$520
- Impella$246
- Dragonfly OCT$152
- ClosureFast$152
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$141
- NEXLIZET$125
- NEXLETOL$125
How this compares
$12,816 in reported general payments places this provider in the 60th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $187,432 |
| XareltoRivaroxaban | 64 | $84,094 |
| EntrestoSacubitril/Valsartan | 38 | $59,166 |
| Repatha SureclickEvolocumab | 38 | $49,824 |
| JardianceEmpagliflozin | 26 | $32,179 |
| Metoprolol Succinate | 550 | $8,343 |
| Atorvastatin Calcium | 505 | $5,041 |
| Amlodipine Besylate | 356 | $3,339 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $3,105 |
| ClopidogrelClopidogrel Bisulfate | 214 | $2,844 |
| Losartan Potassium | 215 | $2,662 |
| Ezetimibe | 65 | $1,771 |
| Potassium Chloride | 116 | $1,744 |
| Carvedilol | 126 | $1,536 |
| Bumetanide | 37 | $1,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $187,432132 claims |
| Johnson & JohnsonXarelto | $43 | $84,09464 claims |
| NovartisEntresto | $107 | $59,16638 claims |
| Boehringer IngelheimJardiance | $158 | $32,17926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Crystal Lake
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Sunil AgarwalSpringfield$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.